NovaQuest Capital Management (NovaQuest), a biopharma and life sciences investment firm specialising in human and animal health investing, has acquired TechAccel’s ownership stake in Covenant Animal Health Partners (Covenant).  Covenant is a novel product development partnership originally formed by TechAccel and Reliance Animal Health Partners (Reliance) in 2018. The acquisition

EverImmune, a biotechnology company specialising in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than EUR5 million (approximately USD6 million) in a Series A funding from undisclosed private investors. EverImmune was created in 2016 as a spinoff from Gustave Roussy;

British Patient Capital has participated in Quell Therapeutics’ USD156 million Series B funding round. The deal is the first life sciences investment from Future Fund: Breakthrough, a GBP375 million programme where British Patient Capital co-invests with private sector investors in innovative R&D-intensive UK companies. Quell Therapeutics (Quell), which is based

NOS 5G Fund, created by NOS and managed by Armilar Venture Partners, and Triple Point Ventures, have co-invested EUR4.4 million in digital health start-up knok.  The investment round also includes participation from previous investors, the Social Innovation Fund and Social and Environmental Impact Fund MSM (Mustard Seed MAZE). The Portuguese

Mednow Inc, a Canadian on-demand virtual pharmacy, has closed a CAD500,000 investment in Doko Medical (Doko Medical) by way of convertible debenture (the Doko Investment), for a 2.8 per cent equity interest at a CAD17.5 million pre-money valuation. Doko Medical is a virtual healthcare provider operating across the US. Currently

Luma Health, a patient engagement platform, has raised USD130 million in a Series C funding round led by FTV Capital, a sector-focused growth equity investment firm, with participation from existing investors.  This latest round brings Luma Health’s total funding raised to USD160 million.  The announcement follows 2x growth year over